The American Journal of Medicine
Volume 119, Issue 10, Supplement 1 , Pages 12-20 , October 2006

Impact of Chronic Obstructive Pulmonary Disease on Quality of Life: The Role of Dyspnea

  • Andrew L. Ries, MD, MPH

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Andrew L. Ries, MD, MPH, University of California, San Diego Medical Center, 200 West Arbor Drive, San Diego, California 92103-8377

References 

  1. Rabe KF . Outcome measures in COPD . Prim Care Respir J . 2004;13:177–178
  2. Jones PW , Bosh TK . Quality of life changes in COPD patients treated with salmeterol . Am J Respir Crit Care Med . 1997;155:1283–1289
  3. Redelmeier DA , Goldstein RS , Min ST , Hyland RH . Spirometry and dyspnea in patients with COPD: when small differences mean little . Chest . 1996;109:1163–1168
  4. O’Donnell DE , Webb KA . Mechanisms of dyspnea in COPD . In:  Mahler DA ,  O’Donnell DE editor. Dyspnea: Mechanisms, Measurement, and Management . 2nd ed. New York: Marcel Dekker; 2005;p. 29–58
  5. Mannino DM , Homa DM , Akinbami LJ , Ford ES , Redd SC . Chronic obstructive pulmonary disease surveillance—United States, 1971–2000 . MMWR Surveill Summ . 2002;51:1–16
  6. American Thoracic Society . Dyspnea: mechanisms, assessment, and management: a consensus statement . Am J Respir Crit Care Med . 1999;159:321–340
  7. Meek PM . Measurement of dyspnea in chronic obstructive pulmonary disease: what is the tool telling you? . Chron Respir Dis . 2004;1:29–37
  8. Pitta F , Troosters T , Spruit MA , Probst VS , Decramer M , Gosselink R . Characteristics of physical activities in daily life in chronic obstructive pulmonary disease . Am J Respir Crit Care Med . 2005;171:972–977
  9. Yusen R . What outcomes should be measured in patients with COPD? . Chest . 2001;119:327–328
  10. Jones PW . Issues concerning health-related quality of life in COPD . Chest . 1995;107:187S–193S
  11. Guyatt GH , Townsend M , Keller J , Singer J , Nogradi S . Measuring functional status in chronic lung disease: conclusions from a randomized control trial . Respir Med . 1991;85(suppl B):17–21
  12. Mahler DA , Tomlinson D , Olmstead EM , Tosteson AN , O’Connor GT . Changes in dyspnea, health status, and lung function in chronic airway disease . Am J Respir Crit Care Med . 1995;151:61–65
  13. Ferrer M , Alonso J , Morera J , et al.  Quality of Life of Chronic Obstructive Pulmonary Disease Study Group   Chronic obstructive pulmonary disease stage and health-related quality of life . Ann Intern Med . 1997;127:1072–1079
  14. Ries AL , Kaplan RM , Limberg TM , Prewitt LM . Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease . Ann Intern Med . 1995;122:823–832
  15. Belman MJ , Botnick WC , Shin JW . Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease . Am J Respir Crit Care Med . 1996;153:967–975
  16. Nishimura K , Izumi T , Tsukino M , Oga T . Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD . Chest . 2002;121:1434–1440
  17. Bestall JC , Paul EA , Garrod R , Garnham R , Jones PW , Wedzicha JA . Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease . Thorax . 1999;54:581–586
  18. Ferris BG . Epidemiology Standardization Project (American Thoracic Society) . Am Rev Respir Dis . 1978;118:1–120
  19. Mahler DA , Weinberg DH , Wells CK , Feinstein AR . The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes . Chest . 1984;85:751–758
  20. Meek PM , Lareau SC . Critical outcomes in pulmonary rehabilitation: assessment and evaluation of dyspnea and fatigue . J Rehabil Res Dev . 2003;40(suppl 2):13–24
  21. Mahler DA , Ward J . Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD . Journal of Chronic Obstructive Pulmonary Disease . 2004;1:1–8
  22. Borg GA . Psychophysical bases of perceived exertion . Med Sci Sports Exerc . 1982;14:377–381
  23. Burdon JG , Juniper EF , Killian KJ , Hargreave FE , Campbell EJ . The perception of breathlessness in asthma . Am Rev Respir Dis . 1982;126:825–828
  24. Celli BR . Pulmonary rehabilitation for COPD: a practical approach for improving ventilatory conditioning . Postgrad Med . 1998;103:159–160 167–158, 173–176
  25. ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel, for the American College of Chest Physicians and the American Association of Cardiovascular and Pulmonary Rehabilitation . Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based guidelines . Chest . 1997;112:1363–1396
  26. Kaplan RM , Ries AL , Reilly J , Mohsenifar Z . Measurement of health-related quality of life in the National Emphysema Treatment Trial . Chest . 2004;126:781–789
  27. Ries AL , Kaplan RM , Myers R , Prewitt LM . Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial . Am J Respir Crit Care Med . 2003;167:880–888
  28. Clini E , Foglio K , Bianchi L , Porta R , Vitacca M , Ambrosino N . In-hospital short-term training program for patients with chronic airway obstruction . Chest . 2001;120:1500–1505
  29. Gigliotti F , Coli C , Bianchi R , et al.  Exercise training improves exertional dyspnea in patients with COPD: evidence of the role of mechanical factors . Chest . 2003;123:1794–1802
  30. Foglio K , Bianchi L , Bruletti G , Battista L , Pagani M , Ambrosino N . Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction . Eur Respir J . 1999;13:125–132
  31. de Torres JP , Pinto-Plata V , Ingenito E , et al.  Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD . Chest . 2002;121:1092–1098
  32. California Pulmonary Rehabilitation Collaborative Group . Effects of pulmonary rehabilitation on dyspnea, quality of life, and healthcare costs in California . J Cardiopulm Rehabil . 2004;24:52–62
  33. Pauwels RA , Buist AS , Calverley PM , Jenkins CR , Hurd SS  GOLD Scientific Committee . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary . Am J Respir Crit Care Med . 2001;163:1256–1276
  34. Casaburi R , Kukafka D , Cooper CB , Witek TJ , Kesten S . Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD . Chest . 2005;127:809–817
  35. Donohue JF , van Noord JA , Bateman ED , et al.  A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol . Chest . 2002;122:47–55
  36. Casaburi R , Mahler DA , Jones PW , et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease . Eur Respir J . 2002;19:217–224
  37. Lung Health Study Research Group . Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease . N Engl J Med . 2000;343:1902–1909
  38. Thompson WH , Carvalho P , Souza JP , Charan NB . Controlled trial of inhaled fluticasone propionate in moderate to severe COPD . Lung . 2002;180:191–201
  39. Paggiaro PL , Dahle R , Bakran I , Frith L , Hollingworth K , Efthimiou J  International COPD Study Group . Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease . Lancet . 1998;351:773–780
  40. Culpitt SV , Maziak W , Loukidis S , Nightingale JA , Matthews JL , Barnes PJ . Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease . Am J Respir Crit Care Med . 1999;160:1635–1639
  41. Vestbo J , Sorensen T , Lange P , Brix A , Torre P , Viskum K . Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial . Lancet . 1999;353:1819–1823
  42. Mahler DA , Wire P , Horstman D , et al.  Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease . Am J Respir Crit Care Med . 2002;166:1084–1091
  43. Calverley P , Pauwels R , Vestbo J , et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial . Lancet . 2003;361:449–456
  44. Hanania NA , Darken P , Horstman D , et al.  The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD . Chest . 2003;124:834–843
  45. Donohue JF , Kalberg C , Emmett A , Merchant K , Knobil K . A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD . Treat Respir Med . 2004;3:173–181

PII: S0002-9343(06)00924-7

doi: 10.1016/j.amjmed.2006.08.003

The American Journal of Medicine
Volume 119, Issue 10, Supplement 1 , Pages 12-20 , October 2006

Article Tools

* Image Usage & Resolution